Application of tenecteplase in the treatment of patients with acute ischemic stroke
10.3760/cma.j.issn.1673-4165.2025.02.007
- VernacularTitle:替奈普酶在急性缺血性卒中患者治疗中的应用
- Author:
Lei ZHA
1
;
Bo ZHU
;
Kun GUO
;
Miao SHI
;
Kexin ZHAO
;
Naibing GU
Author Information
1. 西安交通大学医学院附属西安市中心医院，西安 710000
- Keywords:
Ischemic stroke;
Tenecteplase;
Tissue plasminogen activator;
Thrombolytic therapy;
Endovascular procedures;
Thrombectomy;
Treatment outcome
- From:
International Journal of Cerebrovascular Diseases
2025;33(2):121-126
- CountryChina
- Language:Chinese
-
Abstract:
Acute ischemic stroke is the most common type of stroke, characterized by high mortality, disability, and recurrence rates. Intravenous thrombolysis is the core treatment method. Among them, alteplase is effective as the standard drug, but it has limitations such as narrow time window, high risk of bleeding, and the need for continuous infusion. The new generation of improved drug tenecteplase has the advantages of single intravenous injection and higher fibrin specificity, making it a potential alternative drug to alteplase. In addition, endovascular therapy compensates for the low recanalization rate of large vessel occlusion on the basis of intravenous thrombolysis. This article reviews the clinical progress of teneplase in the treatment of acute ischemic stroke, aiming to provide reference for optimizing the treatment plan of acute ischemic stroke.
